Admin Core

项目总结/摘要：核心A 这个项目的首要主题是题为“神经退行性疾病的病理生物学， “C9 ORF 72重复扩增”是为了确定C9 orf 72重复扩增引起C9 orf 72重复扩增的机制。 肌萎缩侧索硬化症（ALS）和额颞叶痴呆（FTD），并确定新的治疗靶点 和生物标志物，以改善患有c9 ALS/FTD的患者的诊断和预后。 核心A将通过提供科学和财政监督来促进这些目标。核心A将负责 管理计划项目的财务责任，确保研究的道德和负责任的行为， 提供科学指导和问责制，并向NIH和公众报告进展情况。以确保 这项研究计划的成功，核心A还将促进一个多学科的计划， 研究，产生宝贵的生物资源，并促进教育。为了实现其目标，核心A 将致力于实现以下具体目标。具体目标1：提供行政结构和财政监督， 计划项目补助金。具体目标2：定期组织执行委员会会议， 科学管理和促进一体化和研究目标的不断进步。具体 目标3：设立外部咨询委员会，举行年度会议，并向大会报告进展情况。 NINDS。具体目标4：确保临床研究符合伦理行为标准， 研究和人类受试者的安全。具体目标5：向NIH报告进展并确保依从性 NIH公共获取政策。具体目标6：促进关于ALS和相关疾病的教育， 鼓励P01科学家和临床医生参与患者和护理人员支持小组。

PROJECT SUMMARY/ABSTRACT: CORE A The overarching theme of this program project renewal entitled “Pathobiology of Neurodegeneration in C9ORF72 Repeat Expansion” is to determine the mechanisms by which C9orf72 repeat expansions cause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), and identify novel therapeutic targets and biomarkers in order to improve the diagnosis of and prognosis for patients suffering from c9ALS/FTD. Core A will facilitate these goals by providing scientific and fiscal oversight. Core A will be responsible for managing fiscal responsibilities for the program project, ensuring ethical and responsible conduct of research, providing scientific direction and accountability, and reporting progress to the NIH and to the public. To assure the success of this research proposal, Core A will also foster a multidisciplinary program that advances research, generates valuable biological resources, and promotes education. To accomplish its goals, Core A will pursue the following specific aims. Specific Aim 1: Provide administrative structure and fiscal oversight for the program project grant. Specific Aim 2: Organize regular meetings of the Executive Committee to assist in the scientific administration and to facilitate integration and continuing progress on research aims. Specific Aim 3: Establish an External Advisory Committee, conduct annual meetings, and report progress to the NINDS. Specific Aim 4: Ensure that the clinical research conforms to the standards of the ethical conduct of research and the safety of human subjects. Specific Aim 5: Report progress to NIH and ensure compliance with the NIH Public Access policy. Specific Aim 6: Promote education on ALS and related disorders, and encourage P01 scientists and clinicians to participate in patient and caregiver support groups.